[{"id":"5896371c-1ef5-48dc-96cb-56888e31ddde","acronym":"","url":"https://clinicaltrials.gov/study/NCT07150247","created_at":"2025-09-06T13:44:15.174Z","updated_at":"2025-09-06T13:44:15.174Z","phase":"Phase 2","brief_title":"Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer","source_id_and_acronym":"NCT07150247","lead_sponsor":"Sun Yat-sen University","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2025-09-02"},{"id":"883429dd-80b1-4a90-8bbc-e9d0771addf2","acronym":"","url":"https://clinicaltrials.gov/study/NCT07135804","created_at":"2025-08-30T14:01:57.585Z","updated_at":"2025-08-30T14:01:57.585Z","phase":"Phase 2","brief_title":"Iparomlimab and Tuvonralimab Injection for Untreated Locally Advanced Nasopharyngeal Carcinoma","source_id_and_acronym":"NCT07135804","lead_sponsor":"Second Affiliated Hospital of Nanchang University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 09/01/2025","start_date":" 09/01/2025","primary_txt":" Primary completion: 04/30/2028","primary_completion_date":" 04/30/2028","study_txt":" Completion: 04/30/2031","study_completion_date":" 04/30/2031","last_update_posted":"2025-08-22"},{"id":"bf382896-655a-44da-bab6-a9973e918517","acronym":"","url":"https://clinicaltrials.gov/study/NCT07082179","created_at":"2025-07-26T13:28:21.688Z","updated_at":"2025-07-26T13:28:21.688Z","phase":"Phase 2","brief_title":"A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small Cell Lung Cancer","source_id_and_acronym":"NCT07082179","lead_sponsor":"Jiangsu Cancer Institute \u0026 Hospital","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 08/01/2025","start_date":" 08/01/2025","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2025-07-24"},{"id":"dd30cd49-1fd8-43e7-b783-449eccebfd62","acronym":"","url":"https://clinicaltrials.gov/study/NCT07070713","created_at":"2025-07-19T14:10:13.961Z","updated_at":"2025-07-19T14:10:13.961Z","phase":"Phase 2","brief_title":"Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRC","source_id_and_acronym":"NCT07070713","lead_sponsor":"Fujian Cancer Hospital","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • Qibeian (iparomlimab/tuvonralimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 07/30/2025","start_date":" 07/30/2025","primary_txt":" Primary completion: 02/28/2028","primary_completion_date":" 02/28/2028","study_txt":" Completion: 08/30/2028","study_completion_date":" 08/30/2028","last_update_posted":"2025-07-17"},{"id":"7f4c6188-6f95-4f28-ad01-406cc4472186","acronym":"","url":"https://clinicaltrials.gov/study/NCT07041788","created_at":"2025-06-28T13:37:36.873Z","updated_at":"2025-06-28T13:37:36.873Z","phase":"Phase 2","brief_title":"Iparomlimab and Tuvonralimab Combined With SFRT and Definitive Chemoradiotherapy in Locoregionally Advanced Bulky HNSCC","source_id_and_acronym":"NCT07041788","lead_sponsor":"Second Affiliated Hospital of Nanchang University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • docetaxel • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 07/10/2025","start_date":" 07/10/2025","primary_txt":" Primary completion: 07/09/2028","primary_completion_date":" 07/09/2028","study_txt":" Completion: 07/09/2030","study_completion_date":" 07/09/2030","last_update_posted":"2025-06-27"},{"id":"09b9b747-24cc-4e7f-8676-9d48960926cb","acronym":"","url":"https://clinicaltrials.gov/study/NCT06936748","created_at":"2025-06-21T13:18:57.455Z","updated_at":"2025-06-21T13:18:57.455Z","phase":"Phase 2","brief_title":"SFRT+Sequential Hypofractionated/Conventional Fractionated RT+Iparomlimab and Tuvonralimab for Relapsed/Refractory Solid Tumors","source_id_and_acronym":"NCT06936748","lead_sponsor":"Second Affiliated Hospital of Nanchang University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/20/2025","start_date":" 06/20/2025","primary_txt":" Primary completion: 06/19/2028","primary_completion_date":" 06/19/2028","study_txt":" Completion: 06/19/2029","study_completion_date":" 06/19/2029","last_update_posted":"2025-06-17"},{"id":"435f6562-3a9d-4c61-986e-62e2329bff47","acronym":"CCGLC-017","url":"https://clinicaltrials.gov/study/NCT06954116","created_at":"2025-06-14T13:51:50.396Z","updated_at":"2025-06-14T13:51:50.396Z","phase":"Phase 2","brief_title":"Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence","source_id_and_acronym":"NCT06954116 - CCGLC-017","lead_sponsor":"Tongji Hospital","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 08/01/2025","start_date":" 08/01/2025","primary_txt":" Primary completion: 12/31/2028","primary_completion_date":" 12/31/2028","study_txt":" Completion: 04/01/2029","study_completion_date":" 04/01/2029","last_update_posted":"2025-06-13"},{"id":"f99e9a96-78aa-4611-a09e-0bb82a397f5e","acronym":"","url":"https://clinicaltrials.gov/study/NCT06967103","created_at":"2025-06-07T15:00:18.246Z","updated_at":"2025-06-07T15:00:18.246Z","phase":"Phase 2","brief_title":"QL1706 for the Neoadjuvant Treatment of HR+/HER2- Breast Cancer","source_id_and_acronym":"NCT06967103","lead_sponsor":"Henan Cancer Hospital","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • epirubicin • Qibeian (iparomlimab/tuvonralimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 238","initiation":"Initiation: 05/20/2025","start_date":" 05/20/2025","primary_txt":" Primary completion: 05/31/2027","primary_completion_date":" 05/31/2027","study_txt":" Completion: 05/30/2029","study_completion_date":" 05/30/2029","last_update_posted":"2025-05-13"},{"id":"297cd590-bacb-40d9-b395-eacfa8bc49d5","acronym":"","url":"https://clinicaltrials.gov/study/NCT06949761","created_at":"2025-09-07T01:25:54.516Z","updated_at":"2025-09-07T01:25:54.516Z","phase":"Phase 1/2","brief_title":"A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of QLC1101 in Combination With Other Therapies in the Treatment of Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation","source_id_and_acronym":"NCT06949761","lead_sponsor":"Qilu Pharmaceutical Co., Ltd.","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • docetaxel • Qibeian (iparomlimab/tuvonralimab) • QL1203"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-04-29"},{"id":"da0d300b-6122-4216-8cdf-188d19179574","acronym":"QL-GasC-QIBA-1001","url":"https://clinicaltrials.gov/study/NCT06766305","created_at":"2025-02-26T07:07:06.834Z","updated_at":"2025-02-26T07:07:06.834Z","phase":"Phase 1/2","brief_title":"QL1706 Combined With SOX Used in Theperioperative Treatment","source_id_and_acronym":"NCT06766305 - QL-GasC-QIBA-1001","lead_sponsor":"Xiangdong Cheng","biomarkers":" HER-2 • PD-L1","pipe":" | ","alterations":" PD-L1 expression • HER-2 expression","tags":["HER-2 • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Qibeian (iparomlimab/tuvonralimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 01/01/2025","start_date":" 01/01/2025","primary_txt":" Primary completion: 02/28/2026","primary_completion_date":" 02/28/2026","study_txt":" Completion: 06/30/2031","study_completion_date":" 06/30/2031","last_update_posted":"2025-01-09"},{"id":"d1ef715c-a9d2-435d-8f89-9b22030ab5c7","acronym":"","url":"https://clinicaltrials.gov/study/NCT06749899","created_at":"2025-02-26T08:08:39.879Z","updated_at":"2025-02-26T08:08:39.879Z","phase":"Phase 3","brief_title":"QL1706 (IPD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.","source_id_and_acronym":"NCT06749899","lead_sponsor":"Sun Yat-sen University","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • Qibeian (iparomlimab/tuvonralimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 580","initiation":"Initiation: 12/19/2024","start_date":" 12/19/2024","primary_txt":" Primary completion: 12/01/2028","primary_completion_date":" 12/01/2028","study_txt":" Completion: 12/01/2030","study_completion_date":" 12/01/2030","last_update_posted":"2024-12-27"},{"id":"1c21f072-efd7-4fab-8b11-da62fb5de78c","acronym":"DUBHE-L-303","url":"https://clinicaltrials.gov/study/NCT05690945","created_at":"2023-01-19T14:59:48.148Z","updated_at":"2024-07-02T16:35:57.383Z","phase":"Phase 3","brief_title":"A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05690945 - DUBHE-L-303","lead_sponsor":"Qilu Pharmaceutical Co., Ltd.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Tevimbra (tislelizumab-jsgr) • Qibeian (iparomlimab/tuvonralimab) • BGB-108"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 650","initiation":"Initiation: 02/01/2023","start_date":" 02/01/2023","primary_txt":" Primary completion: 06/23/2025","primary_completion_date":" 06/23/2025","study_txt":" Completion: 06/23/2025","study_completion_date":" 06/23/2025","last_update_posted":"2023-01-19"},{"id":"dd542ef8-8a3e-4012-9da1-e863fc2acc9a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05446883","created_at":"2022-07-07T16:57:05.494Z","updated_at":"2024-07-02T16:35:59.823Z","phase":"Phase 3","brief_title":"QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer","source_id_and_acronym":"NCT05446883","lead_sponsor":"Qilu Pharmaceutical Co., Ltd.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • cisplatin • carboplatin • paclitaxel • Qibeian (iparomlimab/tuvonralimab) • Ankeda (bevacizumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 498","initiation":"Initiation: 09/23/2022","start_date":" 09/23/2022","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2022-11-30"},{"id":"5cbb739d-8c04-42cf-8b5b-9053e2c55e96","acronym":"DUBHE-L-304","url":"https://clinicaltrials.gov/study/NCT05487391","created_at":"2022-08-04T14:55:24.201Z","updated_at":"2024-07-02T16:36:06.087Z","phase":"Phase 3","brief_title":"A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.","source_id_and_acronym":"NCT05487391 - DUBHE-L-304","lead_sponsor":"Qilu Pharmaceutical Co., Ltd.","biomarkers":" EGFR • PD-L1 • ALK","pipe":" | ","alterations":" ALK fusion","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • paclitaxel • pemetrexed • vinorelbine tartrate • Qibeian (iparomlimab/tuvonralimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 632","initiation":"Initiation: 10/01/2022","start_date":" 10/01/2022","primary_txt":" Primary completion: 10/01/2028","primary_completion_date":" 10/01/2028","study_txt":" Completion: 10/01/2031","study_completion_date":" 10/01/2031","last_update_posted":"2022-08-04"}]